BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9486492)

  • 1. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.
    Pavletic ZS; Joshi SS; Pirruccello SJ; Tarantolo SR; Kollath J; Reed EC; Bierman PJ; Vose JM; Warkentin PI; Gross TG; Nasrati K; Armitage JO; Kessinger A; Bishop MR
    Bone Marrow Transplant; 1998 Jan; 21(1):33-41. PubMed ID: 9486492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
    Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
    Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
    Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
    Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
    Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
    Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis. A single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Zeller W; Krüger W; Erttmann R; Zander AR
    Support Care Cancer; 1997 Jul; 5(4):299-306. PubMed ID: 9257426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery.
    Kalwak K; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Latos-Grazyńska E; Król M; Boguslawska-Jaworska J; Chybicka A
    Br J Haematol; 2002 Jul; 118(1):74-89. PubMed ID: 12100130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
    Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
    Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
    Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.
    Rosenfeld C; Collins R; Piñeiro L; Agura E; Nemunaitis J
    J Clin Oncol; 1996 Apr; 14(4):1314-9. PubMed ID: 8648389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation in children with leukemia.
    Han DK; Baek HJ; Kim SY; Hwang TJ; Kook H
    Yonsei Med J; 2013 Jan; 54(1):62-70. PubMed ID: 23225800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
    Pavletic ZS; Bishop MR; Tarantolo SR; Martin-Algarra S; Bierman PJ; Vose JM; Reed EC; Gross TG; Kollath J; Nasrati K; Jackson JD; Armitage JO; Kessinger A
    J Clin Oncol; 1997 Apr; 15(4):1608-16. PubMed ID: 9193360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.